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MENDELIAN RANDOMIZATION
Urate, Blood Pressure, and Cardiovascular 
Disease
Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials
Dipender Gill ,* Alan C. Cameron ,* Stephen Burgess, Xue Li, Daniel J. Doherty , Ville Karhunen, Azmil H. Abdul-Rahim ,  
Martin Taylor-Rowan, Verena Zuber, Philip S. Tsao , Derek Klarin , VA Million Veteran Program, Evangelos Evangelou,  
Paul Elliott, Scott M. Damrauer , Terence J. Quinn , Abbas Dehghan, Evropi Theodoratou,† Jesse Dawson,† Ioanna Tzoulaki †
ABSTRACT: Serum urate has been implicated in hypertension and cardiovascular disease, but it is not known whether it is 
exerting a causal effect. To investigate this, we performed Mendelian randomization analysis using data from UK Biobank, 
Million Veterans Program and genome-wide association study consortia, and meta-analysis of randomized controlled trials. 
The main Mendelian randomization analyses showed that every 1-SD increase in genetically predicted serum urate was 
associated with an increased risk of coronary heart disease (odds ratio, 1.19 [95% CI, 1.10–1.30]; P=4×10−5), peripheral 
artery disease (1.12 [95% CI, 1.03–1.21]; P=9×10−3), and stroke (1.11 [95% CI, 1.05–1.18]; P=2×10−4). In Mendelian 
randomization mediation analyses, elevated blood pressure was estimated to mediate approximately one-third of the effect of 
urate on cardiovascular disease risk. Systematic review and meta-analysis of randomized controlled trials showed a favorable 
effect of urate-lowering treatment on systolic blood pressure (mean difference, −2.55 mm Hg [95% CI, −4.06 to −1.05]; 
P=1×10−3) and major adverse cardiovascular events in those with previous cardiovascular disease (odds ratio, 0.40 [95% 
CI, 0.22–0.73]; P=3×10−3) but no significant effect on major adverse cardiovascular events in all individuals (odds ratio, 
0.67 [95% CI, 0.44–1.03]; P=0.07). In summary, these Mendelian randomization and clinical trial data support an effect of 
higher serum urate on increasing blood pressure, which may mediate a consequent effect on cardiovascular disease risk. 
High-quality trials are necessary to provide definitive evidence on the specific clinical contexts where urate lowering may 
be of cardiovascular benefit. (Hypertension. 2021;77:383–392. DOI: 10.1161/HYPERTENSIONAHA.120.16547.) 
• Data Supplement
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Urate is a breakdown product of purine metabolism. Its raised levels have been associated with a number of adverse health outcomes including gout, hypertension, 
and cardiovascular disease (CVD).1 However, it remains 
unclear whether these associations represent causal 
effects.2,3 The relationship between serum urate, obesity, 
diet, and other cardiovascular risk factors raises consider-
able potential for confounding and reverse causation.4
The genetic determinants of serum urate levels have 
been increasingly well-characterized.4 This has made 
it possible to identify better instruments for Mendelian 
randomization (MR) analyses investigating the effect of 
genetically predicted serum urate on cardiovascular out-
comes than in previous efforts.3,5–7 The use of variants 
randomly allocated at conception to proxy the effect of 
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to the environmental confounding, measurement error, 
and reverse causation bias that can limit causal infer-
ence in traditional epidemiological approaches.
Preclinical studies support a causal role for urate 
in hypertension.8 Randomized controlled trial (RCT) 
data have shown that both allopurinol and probenecid 
reduce systolic blood pressure (SBP) in hyperuricemic 
adolescents.1,9,10 Pooling of all available trial data can 
offer more precise effect estimates for the effect of 
urate-lowering therapy on blood pressure.11 As elevated 
blood pressure is a risk factor for CVD, it is important to 
clarify any role of SBP in mediating an effect of urate 
on cardiovascular outcomes.
The aim of the current study was to perform MR analy-
ses investigating the association of genetically predicted 
urate levels with SBP and CVD risk using contemporary 
data and compare findings with results obtained from 
updated systematic review and meta-analysis of urate-
lowering RCTs.
METHODS
All data used in this work are either publicly accessible or 
available on request from their original studies, which obtained 
appropriate patient consent and ethical approval. The UK 
Biobank data were accessed through application 236. All 
results generated in this work are presented in either the article 
or its Data Supplement.
Two-Sample MR
The MR analyses have been reported as per the Strengthening 
the Reporting of Observational Studies in Epidemiology-
Mendelian randomization guidelines.12
Genetic Association Estimates
Genetic association estimates for serum urate in 2-sample 
MR were obtained by using the PLINK software to meta-
analyze summary data from  genome-wide association study 
(GWAS) analyses of 110 347 European-ancestry individu-
als and 343 836 White British UK Biobank participants, 
respectively.13–15 Urate estimates in MR analyses are pro-
vided per 1-SD increase, which corresponds to 80.3 μmol/L. 
For consideration of SBP (or diastolic blood pressure/pulse 
pressure) as a mediator in the 2-sample multivariable MR, 
genetic association estimates were obtained from a GWAS 
of 317 195 White British UK Biobank participants, where 
blood pressure was measured using automated readings 
with correction made for any antihypertensive drug use by 
adding 10 mm Hg to the measured reading for SBP and 5 
mm Hg for diastolic blood pressure.16 In contrast, when inves-
tigating SBP as an outcome, genetic association estimates 
were obtained from the International Consortium for Blood 
Pressure GWAS analysis of 287 245 European-ancestry 
individuals (excluding UK Biobank participants).17 A differ-
ent population was considered when studying SBP as an 
Nonstandard Abbreviations and Acronyms
CVD cardiovascular disease
FAST  Febuxostat and Allopurinol Streamlined 
Trial
GWAS genome-wide association study
HEART  Allopurinol and Cardiovascular Out-
comes in Patients With Ischaemic Heart 
Disease
IVW inverse-variance weighted
MACE major adverse cardiovascular event
MR Mendelian randomization
OR odds ratio
PAD peripheral artery disease
RCT randomized controlled trial
SBP systolic blood pressure
Novelty and Significance
What Is New?
• This study found that higher genetically predicted 
serum urate was associated with an increased risk of 
cardiovascular disease, with elevated blood pressure 
mediating approximately one-third of this effect.
• Meta-analysis of randomized controlled trials showed 
a favorable effect of urate lowering on systolic blood 
pressure and cardiovascular events in those with previ-
ous cardiovascular disease but no significant effect on 
cardiovascular events in all individuals.
What Is Relevant?
• Lowering serum urate may represent a therapeutic 
target for reducing blood pressure and risk of cardio-
vascular disease.
Summary
Genetic analyses and clinical trial data support an 
effect of higher serum urate on increasing blood 
pressure, which may mediate a consequent effect on 
cardiovascular disease risk. High-quality trials are nec-
essary to provide definitive evidence on the specific 
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outcome to avoid overlap with the UK Biobank participants 
used to obtain genetic association estimates for urate, as 
this can bias MR estimates.18 SBP estimates are provided 
per 1-SD increase, which corresponds to 18.6 mm Hg. 
Genetic association estimates for CHD were obtained from 
the CARDIoGRAMplusC4D Consortium 1000G multieth-
nic GWAS (77% European ancestry) of 60 801 cases and 
123 504 controls, with a broad and inclusive definition of 
CHD applied.19 Genetic association estimates for periph-
eral artery disease (PAD) were obtained from the Million 
Veterans Program multiethnic (72% European ancestry) 
GWAS of 31 307 cases and 211 753 controls, with case defi-
nitions made using hospital diagnosis and procedure codes.20 
Genetic association estimates for stroke were obtained from 
the MEGASTROKE multiethnic (86% European ancestry) 
GWAS of 67 162 cases and 454 450 controls,21 with the 
stroke definition including both ischemic and hemorrhagic 
etiologies. Genetic association estimates for ischemic stroke 
only (60 341 cases and 454 450 controls) were used in sec-
ondary analyses.21
Genetic Variants Used as Instruments
Genetic instruments for the 2-sample MR were identified as 
single-nucleotide polymorphisms that were associated with 
urate (or SBP, in mediation analyses) at genome-wide sig-
nificance (P<5×10−8) and were in pair-wise linkage disequi-
librium with r2<0.001. Clumping was performed using the 
TwoSampleMR package of R.22 For univariable MR, instrument 
strength was estimated using the F statistic, with variance in 
the exposure explained assessed using the R2 value.23
Statistical Analysis
In all analyses, single-nucleotide polymorphisms were aligned 
by their effect alleles, and no additional consideration was 
made for palindromic variants. Two-sample MR analyses were 
performed to investigate the effect of genetically predicted 
serum urate on CHD, PAD, stroke, and SBP, respectively. A 
Bonferroni threshold (P<0.01) that corrected for multiple 
testing related to the 4 outcomes was used to ascertain 
statistical significance in the main analysis. Inverse-variance 
weighted (IVW) MR was used in the main analysis, with the 
simple median, contamination mixture method, Egger, plei-
otropy residual sum and outlier,24 and multivariable MR25 
(only for CVD outcomes) sensitivity analyses used to explore 
the robustness of the findings to potential pleiotropy of the 
genetic variants. Given the previously demonstrated overlap in 
the genetic determinants of urate with other metabolic traits,4 
the multivariable MR sensitivity analysis adjusted for genetic 
associations of the instruments with body mass index, esti-
mated glomerular filtration rate, type 2 diabetes, serum low-
density lipoprotein cholesterol, serum high-density lipoprotein 
cholesterol, and serum triglycerides together in the same 
model. Such multivariable MR was not performed when con-
sidering SBP as an outcome, due to population overlap with 
the cohorts used to obtain genetic association estimates for 
the metabolic exposures.18 In MR mediation analyses, multi-
variable MR was applied in the 2-sample setting to adjust for 
the genetic association of the instruments with SBP (or dia-
stolic blood pressure/pulse pressure). Network MR was used 
to estimate the proportion of the total effect of urate on each 
cardiovascular outcome that is mediated through SBP.26 SEs 
were estimated using the propagation of error method.
To investigate potential effects of the cardiovascular traits 
on serum urate levels, we also performed IVW MR analyses 
considering genetically predicted CHD, PAD, stroke, and SBP 
as exposures and serum urate levels as the outcome. The 
approach taken was as described above, except that the con-
sidered exposure and outcome were switched.
Further details on the 2-sample MR analyses are provided 
in Methods in the Data Supplement. Statistical analyses for the 
1-sample MR are detailed in Methods in the Data Supplement 
and Table S1 in the Data Supplement.
Systematic Review and Meta-Analysis of RCTs
The systematic review was conducted in accordance with 
the recommendations from the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses statement.27 
The study protocol was registered and published in the 
International Prospective Register of Systematic Reviews 
(CRD42020164589).
Inclusion and Exclusion Criteria
RCTs of pharmacological urate-lowering versus placebo or no 
treatment of duration ≥28 days in patients ≥18 years of age 
were eligible. Studies with cointervention that was inconsistent 
between intervention and control groups or with mixed experi-
mental groups were excluded.
Data Sources and Searches
We conducted a systematic search of multidisciplinary data-
bases across 4 electronic platforms: Medline (Ovid), Embase 
(Ovid), Web of Science (Thomson Reuters), and Cochrane 
Library (Cochrane). Studies published from January 1, 2016, 
to September 30, 2019, were considered. The literature 
search terms matched those used in a previous systematic 
review (Methods in the Data Supplement).10 No language 
restrictions were applied. Reference lists of retrieved articles 
were reviewed to identify additional relevant articles. Data 
were included from studies in previous systematic reviews 
investigating the effects of urate-lowering therapy on SBP 
(searches until June 29, 2016)11 and CVD (searches until 
December 30, 2016).7
Data Extraction
Study details and results were extracted using a predesigned 
template. In the case of crossover trials, only data from the 
first study period (before crossover) were used. Risk of bias 
was assessed in accordance with the Cochrane guidelines.28 
Studies were considered to have a low overall risk of bias if the 
risk of bias was low for all key study domains. All aspects of the 
database search, study selection, data extraction, and risk of 
bias assessment were performed independently by 2 investi-
gators (A.C.C. and D.J.D.), with arbitration to a third investigator 
(A.H.A.-R.) as necessary.
Outcomes
The outcomes considered in the systematic review and 
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cardiovascular event (MACE; cardiovascular death, nonfatal 
myocardial infarction, unstable angina requiring urgent revas-
cularization, or nonfatal stroke). In secondary analysis, we also 
considered MACE in patients with prior CVD, as this would 
likely represent a higher risk population, thus potentially offer-
ing greater statistical power.
Statistical Analysis
Analysis of extracted data was based on modified intention-to-
treat (considering patients who received at least 1 dose of the 
allocated treatment) or intention-to-treat results. If not reported, 
the mean change in SBP pre- and post-treatment was calcu-
lated and the SD was imputed using the propagation of error 
method using a correlation coefficient that was derived from 
the largest study in the meta-analysis that reported SD for SBP 
values at baseline, at end of the study, and for the change in 
SBP.29,30 The measure of effect size was the difference in mean 
SBP, defined as the mean difference between patients treated 
with urate-lowering therapy versus control. A negative value 
of the difference in mean SBP indicates a greater reduction 
of SBP in the urate-lowering therapy group as compared with 
the control group. Overall CVD risk estimates are described in 
terms of odds ratio (OR).
Random-effects IVW meta-analysis was used to pool 
estimates from different studies, and study heterogeneity 
was assessed using the I2 statistic. Cochran Q test was 
used to investigate heterogeneity between the meta-anal-
ysis estimates obtained for risk of MACE in all patients 
as compared with those with previous CVD. Sensitivity 
analyses were conducted including only studies at low 
risk of bias. For the analysis considering SBP as an out-
come, meta-regression was performed to assess the effect 
of baseline SBP on treatment response. Meta-regression 
analyses were also performed to assess the associations 
of baseline serum urate concentration, absolute change 
in serum urate concentration, and proportional change in 
serum urate concentration with treatment response for 
changes in SBP and risk of MACE in all patients. Analyses 
were conducted using the Comprehensive Meta-Analysis 
software, version 3 (Biostat).
RESULTS
Mendelian Randomization
The instruments for urate that were used in the 2-sam-
ple MR are presented in Table S2. The main IVW MR 
showed that higher genetically predicted serum urate 
levels were associated with an increased risk of CHD, 
with OR of 1.19 ([95% CI, 1.10–1.30] P=4×10−5) per 
1-SD increase in genetically predicted urate. Consis-
tent results were obtained in all MR sensitivity analyses 
except MR-Egger, which had wide 95% CIs (Figure 1). 
Higher genetically predicted serum urate was also asso-
ciated with increased risk of both PAD (OR, 1.12 [95% 
CI, 1.03–1.21]; P=9×10−3) and stroke (OR, 1.11 [95% 
CI, 1.05–1.18]; P=2×10−4) in the main IVW analysis, 
with similar results obtained in all MR sensitivity analyses 
Figure 1. Mendelian randomization 
estimates for the effect of 1-SD 
increase in genetically predicted 
serum urate levels on risk of coronary 
heart disease (CHD), peripheral 
artery disease (PAD), and stroke.
Multivariable Mendelian randomization 
(MVMR) adjusting for genetic associations 
of the instrument variants with body mass 
index, estimated glomerular filtration rate, 
type 2 diabetes, low-density lipoprotein 
cholesterol, high-density lipoprotein 
cholesterol, and triglycerides. The outlier-
corrected pleiotropy residual sum and 
outlier (PRESSO) results are presented 
(5 outlier variants were identified for CHD, 
8 for PAD, and 1 for stroke). The Egger 
intercept was 0.005 ([95% CI, 0.001–
0.009] P=0.004) for CHD, 0.005 ([95% 
CI, 0.001–0.009] P=0.003) for PAD, 
and 0.001 ([95% CI, −0.001 to 0.003] 
P=0.24) for stroke. Con-Mix indicates 
contamination mixture; IVW, inverse-
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except MR-Egger, which again had wide 95% CIs (Fig-
ure 1). For the multivariable MR adjusting for genetic 
confounding through body mass index, estimated glo-
merular filtration rate, type 2 diabetes, and lipid traits, 
direct effects of these exposures on risk of the respec-
tive CVD outcomes are presented in Table S3. Consider-
ing SBP, the main IVW and sensitivity MR analyses all 
provided supporting evidence of a causal effect of serum 
urate (IVW estimate in SD units per 1-SD increase in 
genetically predicted urate, 0.09 [95% CI, 0.05–0.12]; 
P=6×10−7; Figure 2). Scatter plots depicting the asso-
ciation of the instrument variants with serum urate and 
the respective outcomes are presented in Figures S1 
through S4.
Performing multivariable MR to adjust for geneti-
cally predicted SBP showed attenuation of the urate 
effect estimates for the CVD outcomes as compared 
with the main IVW univariable MR (Figure 3), support-
ing that part of the effect of urate on these outcomes 
is mediated through SBP. Similar results were obtained 
when considering diastolic or pulse pressure as media-
tors (Figure S5) or when considering only ischemic 
stroke rather than all stroke as an outcome (Figure 
S6). Network MR mediation analysis quantified this 
as 29% (95% CI, 9%–48%) for CHD, 44% (95% CI, 
5%–83%) for PAD, and 45% (95% CI, 14%–76%) for 
stroke. For CHD, there remained evidence of a direct 
effect of urate even after adjusting for SBP (OR, 1.13 
[95% CI, 1.03–1.23]; P=0.01). In contrast for PAD 
and stroke, although the estimate for the direct effect 
of urate that is not mediated through SBP was posi-
tive, the CI crossed the null and the results were not 
statistically significant (PAD: OR, 1.08 [95% CI, 1.00–
1.17]; P=0.07; stroke: OR, 1.06 [95% CI, 0.99–1.12]; 
P=0.10). Direct effects of SBP on the outcomes after 
adjusting for genetically predicted serum urate are pre-
sented in Table S4.
There was no evidence of associations between 
genetically proxied CHD, PAD, stroke, or SBP with serum 
urate levels (Table S5). The results of the 1-sample 
MR analysis were consistent with the abovementioned 
2-sample MR analysis and are detailed in Results in the 
Data Supplement and Tables S6 through S8. Results 
were similar for men and women in sex-stratified analy-
ses (Results in the Data Supplement).
Systematic Review and Meta-Analysis of RCTs
In total, 92 studies were eligible for the systematic review 
and meta-analysis. Regarding the updated searches 
(January 1, 2016, to September 30, 2019), 5353 
records were screened, 30 full texts were assessed for 
eligibility, and 13 studies were identified that fulfilled the 
eligibility criteria (Figure S7). Characteristics of included 
studies that were identified in the updated search are 
presented in Table S9.
The primary analysis of effects on SBP included 15 
studies (Figure S8). The SD for mean SBP change pre- 
and post-treatment was only available for 1 study,29 and 
this was used to impute the SD for mean SBP change 
pre- and post-treatment for the other studies.30 There 
was heterogeneity between the 15 studies included 
(I2=89%), which was mostly attributable to 1 study con-
sidering renal dialysis patients that hid a high risk of bias 
(Table S10; Figure S8).31 Excluding this study, subjects 
treated with urate-lowering therapy had greater reduc-
tion in SBP than subjects in the control group (mean 
difference in SBP, −2.55 [95% CI, −4.06 to −1.05]; 
P=1×10−3; I2=43%; Figure 4). The analysis of MACE 
risk in all patients considered 85 studies, of which 21 
had events (Figure 5), and the analysis of MACE risk in 
patients with prior cardiovascular events considered 10 
studies, of which 7 had events (Figure 6). Urate-lowering 
therapy was not significantly associated with risk of MACE 
in all patients (OR, 0.67 [95% CI, 0.44–1.03]; P=0.07; 
Figure 2. Mendelian randomization 
estimates for the effect of 1-SD 
increase in genetically predicted 
serum urate levels on systolic blood 
pressure.
The outlier-corrected pleiotropy residual 
sum and outlier (PRESSO) results are 
presented (21 outlier variants were 
identified). The Egger intercept was 0.002 
([95% CI, 0.0004–0.003] P=0.02). 
Con-Mix indicates contamination mixture; 
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I2=0%) but was significantly associated with reduction in 
risk of MACE in patients with a prior cardiovascular event 
(OR, 0.40 [95% CI, 0.22–0.73]; P=3×10−3; I2=0%). 
There was no evidence of heterogeneity between the 
estimates obtained from studies considering all patients 
as compared with those restricted to patients with prior 
CVD (Cochran Q P=0.11).
Risk of bias was low in 16 of the 92 included studies 
(Table S10). Risk of bias was low in 1 of the 15 stud-
ies investigating effects on SBP, 16 of the 24 studies 
Figure 3. Inverse-variance weighted 
(IVW) and multivariable Mendelian 
randomization (MVMR) estimates 
for the effect of 1-SD increase in 
genetically predicted serum urate 
levels on risk of coronary heart 
disease (CHD), peripheral artery 
disease (PAD), and stroke.
The MVMR analysis adjusts for the 
associations of the genetic instruments 
with systolic blood pressure. The MVMR 
only adjusted for the associations of the 
genetic instruments with systolic blood 
pressure and not any other trait. OR 
indicates odds ratio.
Figure 4. Forest plot of randomized controlled trial estimates for change in mean systolic blood pressure in patients receiving 
urate-lowering therapy or placebo/no treatment.
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investigating MACE in all patients, and 2 of the 7 studies 
investigating MACE in patients with a prior cardiovascu-
lar event. In sensitivity analyses including only studies at 
low-risk bias, urate-lowering therapy was not significantly 
associated with greater SBP lowering compared with 
control (mean difference in SBP, −7.40 [95% CI, −15.98 
to 1.18]; P=0.09), MACE in all patients (OR, 0.64 [95% 
CI, 0.28–1.46]; P=0.29; I2=0%; Figure S9), or MACE 
in patients with a prior cardiovascular event (OR, 0.59 
[95% CI, 0.18–1.91]; P=0.38; I2=0%; Figure S10).
Meta-regression analysis demonstrated no asso-
ciation of baseline SBP with SBP change following 
urate-lowering therapy (coefficient, −0.01 [95% CI, 
−0.19 to 0.17]; P=0.92; Figure S11). The serum urate 
concentration entry criteria for inclusion in the stud-
ies, mean baseline serum urate concentration, and 
absolute and proportional change in serum urate con-
centration from baseline for studies included in the 
systematic review are presented in Table S11. Meta-
regression demonstrated that higher baseline serum 
urate concentration was associated with greater SBP 
reduction with urate-lowering therapy (coefficient, 
−1.70 [95% CI, −2.81 to −0.60]; P=2×10−3; Figure 
S12). Meta-regression did not identify an associa-
tion of absolute change in serum urate concentra-
tion (P=0.63) or proportional change in serum urate 
concentration (P=0.59) with SBP change with urate-
lowering therapy. Meta-regression did not identify an 
association of baseline serum urate concentration 
(P=0.96), absolute change in urate concentration 
(P=0.71), or proportional change in serum urate con-
centration (P=0.45) with change in MACE risk with 
treatment with urate-lowering therapy.
DISCUSSION
We used a comprehensive framework of MR methodolo-
gies to perform detailed investigation into the association 
of genetically predicted serum urate with CVD outcomes 
and replicated findings in the independent UK Biobank 
population. The MR analyses went beyond recent efforts, 
to consider genetic association estimates from larger 
studies of serum urate. The MR analyses identified con-
sistent evidence for an association between higher genet-
ically predicted serum urate levels with risk of CVD and 
Figure 5. Forest plot of randomized controlled trial estimates for risk of major adverse cardiovascular events in all patients 
receiving urate-lowering therapy or placebo/no treatment.


















Gill et al Urate, Blood Pressure, and Cardiovascular Disease
390  February 2021 Hypertension. 2021;77:383–392. DOI: 10.1161/HYPERTENSIONAHA.120.16547
SBP. Performing multivariable MR to adjust for genetic 
association with SBP attenuated the estimates for the 
CVD outcomes to support that at least some of the effect 
of urate may be mediated through raised blood pressure. 
Updated systematic review and meta-analysis of RCT 
data similarly showed a favorable effect of urate-lower-
ing treatment on SBP, with meta-regression supporting 
a greater effect in individuals with higher baseline urate. 
There was also some trial evidence to support a protec-
tive effect on MACE risk in individuals with prior CVD.
Hyperuricemia has been postulated to cause endothe-
lial dysfunction by increasing oxidative stress,1 and this 
could directly increase risk of CVD through effects on the 
vascular endothelium.1 In an animal model where hyper-
uricemia was induced using a uricase inhibitor, hyper-
tension followed after 3 weeks while controls remained 
normotensive,8 thus representing a second mechanism 
by which urate can increase risk of CVD. The results of 
the FAST (Febuxostat and Allopurinol Streamlined Trial) 
and HEART trials (Allopurinol and Cardiovascular Out-
comes in Patients With Ischaemic Heart Disease) will 
help provide further insight on potential repurposing of 
existing urate-lowering agents for CVD prevention.32,33 
Allopurinol could represent an inexpensive, safe, and 
well-tolerated drug for reducing cardiovascular risk.34
Our current study has several strengths. We trian-
gulate evidence across MR analyses and RCT data to 
provide consistent evidence for a role of serum urate in 
increasing SBP and potentially also increasing CVD risk. 
Our analyses identify a possible mediating role of SBP 
in the pathway from serum urate to CVD risk. In contrast, 
previous MR studies have considered associations of 
the genetic instruments for urate with blood pressure as 
representing genetic confounding.3,5–7 Exclusion of such 
variants or adjustment for their genetic association with 
blood pressure traits, as was done in these studies,3,5–7 
would obscure any true causal effect of genetically pre-
dicted urate on CVD risk. Our present MR analysis also 
incorporated more powerful instruments for serum urate 
than were available previously. The variants used as 
instruments in our 1-sample MR analysis of UK Biobank 
participants explained ≈7.7% of the variance in serum 
urate,4 in contrast to the 5.3% that would be explained 
if selecting instrument variants from the previous largest 
published GWAS of serum urate.13 To further advance on 
previous MR efforts,3,6 our study also incorporated formal 
mediation analyses to investigate blood pressure as a 
mediator in the effect of serum urate on CVD risk. Simi-
larly, our systematic review and meta-analysis of RCTs 
updated evidence from previous efforts to consider an 
additional 13 studies.10,11
Study Limitations
Our work also has limitations. The MR approach makes a 
series of modeling assumptions and in particular requires 
that the genetic variants used as instruments do not 
affect the considered outcomes through pathways that 
are independent of urate. While this can never be com-
pletely excluded, we performed a range of MR sensitivity 
analyses that make distinct assumptions on the presence 
of pleiotropic variants and generally found consistent 
estimates. The MR-Egger method generated wide 95% 
CIs in all analyses and was likely of limited reliability due 
Figure 6. Forest plot of randomized controlled trial estimates for risk of major adverse cardiovascular events in patients with 
existing cardiovascular disease receiving urate-lowering therapy or placebo/no treatment.
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to the strength of the urate instruments being correlated 
to their direct effects on the CVD outcomes under con-
sideration.4,35 The genetic analyses were also based pre-
dominantly on individuals of European ancestry and thus 
may not apply to other populations or settings. Finally, 
use of urate-lowering mediation was not accounted for in 
MR analyses. Considering the meta-analysis of RCTs, the 
majority (76 of 92) of studies had a high or undetermined 
risk of bias, and there was heterogeneity in the results of 
RCTs measuring change in SBP following urate-lowering 
therapy, possibly related to study design, in turn limiting 
the strength of conclusions that can be drawn. Renal 
dialysis patients were not included in the MR analyses, 
and these results may, therefore, not apply to such popu-
lations. Finally, it may be that the identified effect of urate 
lowering on MACE in meta-analysis of trials considering 
patients with previous CVD but not in all patients or when 
restricting to studies with low risk of bias was attributable 
to insufficient statistical power.
Perspectives
We have found consistent MR and RCT evidence for an 
effect of higher serum urate levels on increasing SBP, 
with further evidence also supporting a potential effect 
on risk of CVD. High-quality trial data are now necessary 
to provide definitive evidence on the specific clinical con-
texts where urate lowering may be of cardiovascular ben-
efit, with some large-scale studies already underway.32,33
ARTICLE INFORMATION
Received October 19, 2020; accepted November 25, 2020.
Affiliations
Department of Epidemiology and Biostatistics, School of Public Health (D.G., V.K., 
V.Z., E.E., P.E., A.D., I.T.), Department of Medicine, Centre for Pharmacology and 
Therapeutics, Hammersmith Campus (D.G.), MRC Centre for Environment and 
Health, School of Public Health (P.E., A.D., I.T.), and British Heart Foundation Cen-
tre of Research Excellence (P.E.), Imperial College London, United Kingdom. Novo 
Nordisk Research Centre Oxford, Old Road Campus, United Kingdom (D.G.). 
Clinical Pharmacology and Therapeutics Section, Institute of Medical and Bio-
medical Education and Institute for Infection and Immunity, St George’s, University 
of London, United Kingdom (D.G.). Clinical Pharmacology Group, Pharmacy and 
Medicines Directorate, St George’s University Hospitals NHS Foundation Trust, 
London, United Kingdom (D.G.). Institute of Cardiovascular and Medical Sciences 
(A.C.C., D.J.D., M.T.-R., T.J.Q., J.D.) and Institute of Neuroscience and Psychol-
ogy (A.H.A.-R.), University of Glasgow, United Kingdom. MRC Biostatistics Unit, 
Cambridge Institute of Public Health, United Kingdom (S.B., V.Z.). Cardiovascular 
Epidemiology Unit, Department of Public Health and Primary Care, University of 
Cambridge, United Kingdom (S.B.). Centre for Global Health, Usher Institute (X.L., 
E.T.) and Edinburgh Cancer Research Centre, Institute of Genetics and Molecular 
Medicine (E.T.), University of Edinburgh, United Kingdom. School of Public Health, 
Zhejiang University, Hangzhou, China (X.L.). VA Palo Alto Health Care System, 
CA (P.S.T.). Department of Medicine, Stanford University School of Medicine, CA 
(P.S.T.). Malcom Randall VA Medical Center, Gainesville, FL (D.K.). Center for Ge-
nomic Medicine, Massachusetts General Hospital, Harvard Medical School, MA 
(D.K.). Program in Medical and Population Genetics, Broad Institute of MIT and 
Harvard, MA (D.K.). Division of Vascular Surgery and Endovascular Therapy, Uni-
versity of Florida School of Medicine, Gainesville, FL (D.K.). Department of Hy-
giene and Epidemiology, University of Ioannina Medical School, Greece (E.E., I.T.). 
UK Dementia Research Institute at Imperial College London, United Kingdom 
(P.E., A.D., I.T.). Imperial Biomedical Research Centre, Imperial College London and 
Imperial College NHS Healthcare Trust, United Kingdom (P.E., I.T.). Health Data 
Research UK, London (P.E.). Corporal Michael J. Crescenz VA Medical Center, PA 
(S.M.D.). Department of Surgery, University of Pennsylvania Perelman School of 
Medicine, Philadelphia (S.M.D.).
Acknowledgments
We acknowledge the contributors of the data used in this work: CARDIoGRAM-
plusC4D, CKDGen, DIAGRAM, Genetic Investigation of Anthropometric Traits, 
Global Lipids Genetics Consortium, International Consortium for Blood Pressure, 
MEGASTROKE, Million Veterans Program, and UK Biobank. D. Gill, J. Dawson, 
A.C. Cameron, E. Theodoratou, and I. Tzoulaki designed the study. D. Gill, X. Li, A.C. 
Cameron, D.J. Doherty, A.H. Abdul-Rahim, and M. Taylor-Rowan had full access to 
the data and performed the analysis. All authors interpreted the results. D. Gill, J. 
Dawson, A.C. Cameron, and I. Tzoulaki drafted the manuscript. All authors critically 
revised the manuscript for intellectual content. All authors approved the submit-
ted version and are accountable for the integrity of the work.
Sources of Funding
This work was supported by funding from the US Department of Veterans Affairs 
Office of Research and Development, Million Veteran Program Grant MVP003 
(I01-BX003362), and the UK National Institute for Health Research Cambridge 
Biomedical Research Centre. This publication does not represent the views of 
the Department of Veterans Affairs of the US Government. D. Gill is funded by 
the Wellcome 4i Clinical PhD Program (203928/Z/16/Z) and the British Heart 
Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial Col-
lege London. S. Burgess is supported by Sir Henry Dale Fellowship jointly funded 
by the Wellcome Trust and the Royal Society (grant No. 204623/Z/16/Z). V. Kar-
hunen is funded by the European Union Horizon 2020 research and innovation 
program under the Marie Sklodowska-Curie grant (721567). P. Elliott acknowl-
edges support from the British Heart Foundation (RE/18/4/34215), the Medical 
Research Council (MR/S019669/1), the National Institute for Health Research 
Imperial Biomedical Research Centre, Imperial College London (RDF03), the UK 
Dementia Research Institute (DRI) at Imperial College London funded by UK DRI, 
Ltd (funded by the Medical Research Council, Alzheimer’s Society, Alzheimer’s 
Research UK), and Health Data Research (HDR) UK London funded by HDR 
UK, Ltd (funded by a consortium led by the Medical Research Council 1004231). 
S.M. Damrauer was supported by the Department of Veterans Affairs Office of 
Research and Development (IK2-CX001780). E. Theodoratou is funded by a 
Cancer Research UK Career Development Fellowship (C31250/A22804). The 
MEGASTROKE project received funding from sources specified at http://www.
megastroke.org/acknowledgments.html. Details of all MEGASTROKE authors 
are available at http://www.megastroke.org/authors.html.
Disclosures
D. Gill is employed part-time by Novo Nordisk outside the submitted work. E. 
Evangelou acknowledges consultancy fees from OpenDNA outside of the sub-
mitted work. S.M. Damrauer has received grants from the US Department of Vet-
erans Affairs and Renalytix AI plc outside the submitted work. J. Dawson and 
T.J. Quinn have received charitable research income to conduct clinical trials of 
allopurinol use in people with stroke. The other authors report no conflicts.
REFERENCES
 1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J 
Med. 2008;359:1811–1821. doi: 10.1056/NEJMra0800885
 2. Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP, Campbell H, 
Theodoratou E. Serum uric acid levels and multiple health outcomes: umbrella 
review of evidence from observational studies, randomised controlled tri-
als, and Mendelian randomisation studies. BMJ. 2017;357:j2376. doi: 
10.1136/bmj.j2376
 3. Li X, Meng X, He Y, Spiliopoulou A, Timofeeva M, Wei WQ, Gifford A, Yang T, 
Varley T, Tzoulaki I, et al. Genetically determined serum urate levels and 
cardiovascular and other diseases in UK Biobank cohort: a phenome-
wide mendelian randomization study. PLoS Med. 2019;16:e1002937. doi: 
10.1371/journal.pmed.1002937
 4. Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, Sieber KB, 
Qiu C, Gorski M, Yu Z, et al; German Chronic Kidney Disease Study; Life-
lines Cohort Study; V. A. Million Veteran Program. Target genes, variants, 
tissues and transcriptional pathways influencing human serum urate levels. 
Nat Genet. 2019;51:1459–1474. doi: 10.1038/s41588-019-0504-x
 5. Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, Young R, Shah N, 
Samuel M, Sheikh N, et al. Causal assessment of serum urate levels in car-
diometabolic diseases through a Mendelian Randomization Study. J Am Coll 


















Gill et al Urate, Blood Pressure, and Cardiovascular Disease
392  February 2021 Hypertension. 2021;77:383–392. DOI: 10.1161/HYPERTENSIONAHA.120.16547
 6. Efstathiadou A, Gill D, McGrane F, Quinn T, Dawson J. Genetically 
determined uric acid and the risk of cardiovascular and neurovascu-
lar diseases: a Mendelian Randomization Study of outcomes inves-
tigated in randomized trials. J Am Heart Assoc. 2019;8:e012738. doi: 
10.1161/JAHA.119.012738
 7. White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, Shah S, Kruger FA, 
Giambartolomei C, Swerdlow DI, et al; International Consortium for Blood 
Pressure (ICBP); UCLEB (University College London-London School 
of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma 
urate concentration and risk of coronary heart disease: a Mendelian ran-
domisation analysis. Lancet Diabetes Endocrinol. 2016;4:327–336. doi: 
10.1016/S2213-8587(15)00386-1
 8. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, 
Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pres-
sure in the rat by a novel crystal-independent mechanism. Hypertension. 
2001;38:1101–1106. doi: 10.1161/hy1101.092839
 9. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure 
of adolescents with newly diagnosed essential hypertension: a randomized 
trial. JAMA. 2008;300:924–932. doi: 10.1001/jama.300.8.924
 10. Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, 
d’Avila R, Morsch ALB, da Silva Stein F, Campos GGD. Xanthine oxidase 
inhibitors for prevention of cardiovascular events: a systematic review and 
meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 
2018;18:24. doi: 10.1186/s12872-018-0757-9
 11. Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood 
pressure: systematic review and meta-analysis. Ann Med. 2017;49:142–
156. doi: 10.1080/07853890.2016.1243803
 12. Davey Smith G, Davies NM, Dimou N, Egger M, Gallo V, Golub R, 
Higgins JPT, Langenberg C, Loder EW, Richards JB, et al. STROBE-MR: 
guidelines for strengthening the reporting of Mendelian randomiza-
tion studies. PeerJ Preprints. Preprint posted online July 15, 2019. doi: 
10.7287/peerj.preprints.27857v1
 13. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, 
Pistis G, Ruggiero D, O’Seaghdha CM, Haller T, et al; LifeLines Cohort 
Study; CARDIoGRAM Consortium; DIAGRAM Consortium; ICBP Con-
sortium; MAGIC Consortium. Genome-wide association analyses iden-
tify 18 new loci associated with serum urate concentrations. Nat Genet. 
2013;45:145–154. doi: 10.1038/ng.2500
 14. Neale Lab. Rapid GWAS of Thousands of Phenotypes in the UK Biobank 
2020. Accessed June 16, 2020. http://www.nealelab.is/uk-biobank/
ukbround2announcement.
 15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, 
Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum 
Genet. 2007;81:559–575. doi: 10.1086/519795
 16. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, Wootton RE, 
Munafò MR, Hemani G, Malik R, et al. Understanding the consequences 
of education inequality on cardiovascular disease: mendelian randomisation 
study. BMJ. 2019;365:l1855. doi: 10.1136/bmj.l1855
 17. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, 
Ntritsos G, Dimou N, Cabrera CP, Karaman I, et al; Million Veteran Program. 
Genetic analysis of over 1 million people identifies 535 new loci associ-
ated with blood pressure traits. Nat Genet. 2018;50:1412–1425. doi: 
10.1038/s41588-018-0205-x
 18. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in 
two-sample Mendelian randomization. Genet Epidemiol. 2016;40:597–608. 
doi: 10.1002/gepi.21998
 19. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, 
Kyriakou T, Nelson CP, Hopewell JC, et al. A comprehensive 1,000 genomes-
based genome-wide association meta-analysis of coronary artery disease. 
Nat Genet. 2015;47:1121–1130. doi: 10.1038/ng.3396
 20. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, 
Lee KM, Shao Q, Huffman JE, Natarajan P, et al; VA Million Veteran 
Program. Genome-wide association study of peripheral artery disease 
in the Million Veteran Program. Nat Med. 2019;25:1274–1279. doi: 
10.1038/s41591-019-0492-5
 21. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, 
Mishra A, Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, et 
al; AFGen Consortium; Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium; International Genomics of Blood 
Pressure (iGEN-BP) Consortium; INVENT Consortium; STARNET; Bio-
Bank Japan Cooperative Hospital Group; COMPASS Consortium; EPIC-
CVD Consortium; EPIC-InterAct Consortium; International Stroke Genetics 
Consortium (ISGC); METASTROKE Consortium; Neurology Working Group 
of the CHARGE Consortium; NINDS Stroke Genetics Network (SiGN); 
UK Young Lacunar DNA Study; MEGASTROKE Consortium. Multiancestry 
genome-wide association study of 520,000 subjects identifies 32 loci asso-
ciated with stroke and stroke subtypes. Nat Genet. 2018;50:524–537. doi: 
10.1038/s41588-018-0058-3
 22. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, 
Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-base platform 
supports systematic causal inference across the human phenome. eLife. 
2018;7:e34408.
 23. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, 
Davey Smith G, Sterne JA. Using multiple genetic variants as instrumental 
variables for modifiable risk factors. Stat Methods Med Res. 2012;21:223–
242. doi: 10.1177/0962280210394459
 24. Slob EAW, Burgess S. A comparison of robust Mendelian randomization 
methods using summary data. Genet Epidemiol. 2020;44:313–329. doi: 
10.1002/gepi.22295
 25. Burgess S, Dudbridge F, Thompson SG. Re: “multivariable Mendelian 
randomization: the use of pleiotropic genetic variants to estimate causal 
effects”. Am J Epidemiol. 2015;181:290–291. doi: 10.1093/aje/kwv017
 26. Carter AR, Sanderson E, Hammerton G, Richmond RC, Smith GD, Heron J, 
Taylor AE, Davies NM, Howe LD. Mendelian randomisation for mediation 
analysis: current methods and challenges for implementation. bioRxiv. Pre-
print posted online November 8, 2019. doi: 10.1101/835819
 27. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analyses: the PRISMA 
statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535
 28. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, 
Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; 
Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool 
for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 
10.1136/bmj.d5928
 29. McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid 
lowering on renin-angiotensin-system activation and ambulatory BP: a ran-
domized controlled trial. Clin J Am Soc Nephrol. 2017;12:807–816. doi: 
10.2215/CJN.10771016
 30. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, 
Thomas J. Updated guidance for trusted systematic reviews: a new 
edition of the Cochrane Handbook for systematic reviews of inter-
ventions. Cochrane Database Syst Rev. 2019;10:ED000142. doi: 
10.1002/14651858.ED000142
 31. Omrani H, Muhammad S, Sadeghi K, Raeisi D, Hashemian A. The effect of 
allopurinol treatment regimen on serum uric acid and arterial blood pressure 
in hemodialysis patients. J Kermanshah Univ Med. 2016;20:56–61.
 32. MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, 
Hallas J, Hawkey CJ, Ralston S, Walters M, et al; Members of the FAST 
Study Group. Protocol of the Febuxostat versus Allopurinol Streamlined Trial 
(FAST): a large prospective, randomised, open, blinded endpoint study com-
paring the cardiovascular safety of allopurinol and febuxostat in the man-
agement of symptomatic hyperuricaemia. BMJ Open. 2014;4:e005354. doi: 
10.1136/bmjopen-2014-005354
 33. Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, Taggar J, Wei L, 
Struthers AD, MacDonald TM; ALL-HEART Study Group. Multicentre, pro-
spective, randomised, open-label, blinded end point trial of the efficacy of 
Allopurinol Therapy in Improving Cardiovascular Outcomes in Patients With 
Ischaemic Heart Disease: protocol of the ALL-HEART study. BMJ Open. 
2016;6:e013774. doi: 10.1136/bmjopen-2016-013774
 34. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose 
allopurinol on exercise in patients with chronic stable angina: a randomised, 
placebo controlled crossover trial. Lancet. 2010;375:2161–2167. doi: 
10.1016/S0140-6736(10)60391-1
 35. Burgess S, Thompson SG. Interpreting findings from Mendelian randomiza-





 http://ahajournals.org by on January 18, 2021
